Medtronic

According to Piper Jaffray, Medtronic (NYSE: MDT) price target is $44. Piper Jaffray said that, while more negative focus on InFuse will likely continue to pressure spine division sales, the larger portion of MDT's spine business, core constructs, are trending upward. “Our price target of $44 is...

J.P. Morgan is out with its report today on Medtronic (NYSE: MDT), maintaining Neutral. In a note to clients, J.P. Morgan writes, "Our $41 December 2011 price target values Medtronic at 11.0x our CY12 EPS forecast. This is a modest discount to the company's current NTM multiple of 11.6x, and...

Bank of America Merrill Lynch is out with its report today on Mectronic (NYSE: MDT), maintaining Neutral. In a note to clients, Bank of America Merrill Lynch writes, "Overall, MDT's top-line outlook is slightly below the group, its cash flow generation is well above average, its FX risk is low,...

Morgan Stanley reiterated its Equal-weight rating on Medtronic (NYSE: MDT). At the moment, Morgan Stanley does not have a price target placed on the company's stock. On Tuesday, Medtronic added 1.11% to its value to end the day at $39.01. Its shares lost all of yesterday's gains in today's pre-...

Deutsche Bank reiterated its rating on Medtronic (NYSE: MDT) at Buy. At the same time, Deutsche Bank left its price target on the company's stock unchanged at $45. On Tuesday, Medtronic added 1.11% to its value to end the day at $39.01. Its shares lost all of yesterday's gains in today's pre-market...

Deutsche Bank has lowered the price target on Medtronic (NYSE: MDT) from $46 to $45 and maintains its Buy rating.

The U.S.-Russia Business Council Board Members, led by USRBC Chairman Klaus Kleinfeld of Alcoa, met today with President Medvedev in St. Petersburg at The St. Petersburg International Economic Forum to present him with a letter voicing their full support for the Russian Federation's accession to...

Oppenheimer is out with its report today on Medtronic (NYSE: MDT), maintaining Outperform. In a note to clients, Oppenheimer writes, "We focus on MDT's near- and long-term pipeline, cost savings programs and strong FCF (over 40-50% being returned to shareholders in the form of dividends and stock...

Wedbush reiterated its Neutral rating and PT of $36 on Medtronic (NYSE: MDT). In a research report published today, Wedbush states, "We are maintaining our NEUTRAL rating and $36 price target. Our price target represents a multiple of 10x our FY2012 EPS estimate, which is in line with the large-...

Piper Jaffray is out with its report today on Medtronic (NYSE: MDT), maintaining Overweight. In a note to clients, Piper Jaffray writes, "Growth continued to elude MDT; we see the value thesis of strong global brands, consistent cash flow, and a low multiple, remaining intact. In our view, if the...

According to J.P. Morgan, Medtronic (NYSE: MDT) reported mixed F4Q11 results Tuesday morning, as adjusted EPS of $0.90 (+1.2%) fell $0.02 short of consensus. J.P. Morgan said that on the top line, revenues of $4.295B (+2.4%) came in $10M better than the Street, but organic growth was just 0.2% in...

Morgan Stanley provided color on Medtronic (NYSE: MDT) after the company announced its quarterly report. In a research report published today, Morgan Stanley expressed its belief that the earnings per share guidance of $3.43 - $3.50 might be conservative. In the report, Morgan Stanley states, "...

Citi reiterated its Buy rating on Medtronic (NYSE: MDT). At the same time, Citi left its price target unchanged at $49 after Medtronic announced its quarterly results. In a research report published today, Citi states, "MDT's F4Q11 results weren't as bad as we feared as several new products...

Deutsche Bank reiterated its Buy rating on Medtronic (NYSE: MDT) after the company announced its quarterly results. In a research report published today, Deutsche Bank states, "F4Q sales were in line but EPS of $0.90 was $0.02 below First Call Cons and $0.03 below implied guidance due to Greece...

Medtronic (NYSE: MDT) is scheduled to report fiscal fourth-quarter 2011 results before the markets open tomorrow, May 24. Analysts expect the medical device maker to announce that per-share earnings inched up 3 cents from a year ago to $0.93. That consensus estimate is unchanged from 60 days ago....